Latest Headlines

Latest Headlines

Novartis CEO says company to make heart failure drug Entresto at Singapore plant

Novartis will make its heart failure drug Entresto at a Singapore site starting this year, CEO Joe Jimenez told the Straits Times newspaper, adding that plans are also underway to expand contact lens manufacturing in the city-state.

Singapore's iX Biopharma notes success in PhII trials of pain candidate

Singapore-listed iX Biopharma reported successful Phase IIa and IIb clinical trials for pain relief lead candidate Wafermine, setting the stage for moving to Phase III, according to the  Business Times.

ASLAN gets PhII nod for bile duct cancer candidate in Singapore, Taiwan

Singapore-based cancer and autoimmune biotech ASLAN Pharmaceutical said it has won clinical trial approval nods in Singapore and Taiwan for Phase II work on ASLAN001 (varlitinib) in second-line cholangiocarcinoma, or aggressive bile duct cancer, marking stepped-up activity for a candidate that recently obtained U.S. FDA orphan designation.

Services grow in Singapore with Asian clinical, manufacturing biologics boom

Singapore has gathered pace as a place for companies in Asia to source services related to biologic clinical and manufacturing with recent additions in the city-state highlighting niches in a growing market.

Singapore's Asian American Medical eyes oncology expansion in southern China

Singapore-listed Asian American Medical Group said it paid S$19.6 million ($13.9 million) to buy 60% of Rich Tree Land to develop an oncology diagnostics and treatment center in Zhuhai, southern China. 

ASLAN gets U.S. FDA orphan designation on ASLAN001

Singapore-based ASLAN Pharmaceuticals has received a U.S. FDA orphan designation for candidate ASLAN001 (varlitinib), a pan-HER inhibitor, as a treatment for cholangiocarcinoma,  a rare and very aggressive form of bile duct cancer which has no cure, the company said in a press release.

ASLAN and Singapore's NCCS plan studies on Asia-prevalent cancers

Singapore-based ASLAN Pharmaceuticals has signed an understanding with the National Cancer Centre of Singapore (NCCS) to study novel combination therapies to treat gastric cancer, hepatocellular carcinoma and cholangiocarcinoma, in its second move in this month to explore wider avenues for its existing clinical trial candidates.

Singapore's biopharma industry: Where the jobs are

Hays Recruiting in Singapore says jobs in biopharma niches in manufacturing, regulatory and sales are up for grabs in the island nation, topping its latest quarterly regional outlook of skills in demand through September 2015, according to a press release.

Singapore's big biotech push yields its first clinical contender

Singapore, a nation working to raise its profile in the biopharma world, has kicked off the first-ever clinical trial of a locally invented drug, working with Duke University on a novel cancer treatment it hopes will spur more R&D.

GSK doubles down on Singapore continuous processing plant

Several years ago, GlaxoSmithKline committed $50 million to set up an antibiotics facility in Singapore to do continuous processing, a radically different manufacturing approach that has a much smaller footprint, and so much lower operating costs and less environmental impact, than traditional batch processing. The drugmaker now says it is ready to embark on a £38 million expansion there.